Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: dorightbythem who wrote (1199)	10/22/2025 11:02:11 AM
From: jargonweary	3 Recommendations Recommended By CCS648 erippetoe luckydog88 Respond to of 1216

Yep. And the market is totally unimpressed with all of this. Significant further dilution is being foreshadowed here. This is feeling more and more like a mistake getting into this. I have been waiting on positive news but all we get is breathless PSS hype about how only he has figured out how to cure toenail fungus or something which is followed by dilution and the inevitable decline in share price. Feeling more and more as if waiting further for happy news might be a fools errand.

To: dorightbythem who wrote (1199)	10/22/2025 2:49:19 PM
From: bobbseytwins2001	4 Recommendations Recommended By CCS648 JJINV Olecranon waitwatchwander Read Replies (2) \| Respond to of 1216

Have to dispute the "no trials or data". We see trials everywhere to a fault. It's hard to picture PSS intentionally blowing up his net worth by seeing IBRX fail. We are worried about our shares, but PSS has shown that he cares about his as well. In the background lurks Anktiva, a compound that is certainly worth more than $2.40 per share. But, with all the negativity here going into third quarter sales and several possibilities including more Anktiva approvals in the future this might be the time to be contrary.